Ono Pharmaceutical Co., Ltd. – OTC:OPHLF

Ono Pharmaceutical Co., Ltd. stock price today

$11.4
+1.80
+18.75%
Financial Health
0
1
2
3
4
5
6
7
8
9

Ono Pharmaceutical Co., Ltd. stock price monthly change

-29.20%
month

Ono Pharmaceutical Co., Ltd. stock price quarterly change

-29.20%
quarter

Ono Pharmaceutical Co., Ltd. stock price yearly change

-45.72%
year

Ono Pharmaceutical Co., Ltd. key metrics

Market Cap
10.48B
Enterprise value
739.78B
P/E
5.88
EV/Sales
1.47
EV/EBITDA
4.41
Price/Sales
1.42
Price/Book
0.87
PEG ratio
N/A
EPS
141.13
Revenue
408.22B
EBITDA
102.44B
Income
68.72B
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
24.17%
Oper. margin
30.46%
Gross margin
74.69%
EBIT margin
30.46%
EBITDA margin
25.09%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Ono Pharmaceutical Co., Ltd. stock price history

Ono Pharmaceutical Co., Ltd. stock forecast

Ono Pharmaceutical Co., Ltd. financial statements

Ono Pharmaceutical Co., Ltd. (OTC:OPHLF): Profit margin
Dec 2021 97.35B 18.33B 18.83%
Mar 2022 89.93B 15.89B 17.68%
Mar 2023 108.16B 17.06B 15.78%
Mar 2024 112.76B 17.43B 15.46%
Ono Pharmaceutical Co., Ltd. (OTC:OPHLF): Earnings per share (EPS)
2024-10-31 0.3516 0.24
2.76%
Yield TTM
Ono Pharmaceutical Co., Ltd. (OTC:OPHLF): Payout ratio
Payout ratio 31.25%
Ono Pharmaceutical Co., Ltd. (OTC:OPHLF): Dividend Yield
2020 2.34%
2021 1.37%
2022 1.77%
2023 2.19%
2024 3.18%
Ono Pharmaceutical Co., Ltd. (OTC:OPHLF): Debt to assets
Sep 2022 805008000000 94.63B 11.76%
Dec 2022 830539000000 103.23B 12.43%
Mar 2023 882437000000 134.62B 15.26%
Mar 2024 913668000000 115.06B 12.59%
Ono Pharmaceutical Co., Ltd. (OTC:OPHLF): Cash Flow
Dec 2021 -12.97B 23.44B -29.26B
Mar 2022 34.43B -12.01B -16.00B
Mar 2023 44.54B -55.40B -1.61B
Mar 2024 49.16B 28.70B -14.49B

Ono Pharmaceutical Co., Ltd. alternative data

Ono Pharmaceutical Co., Ltd. (OTC:OPHLF): Employee count
Aug 2023 3,761
Sep 2023 3,761
Oct 2023 3,761
Nov 2023 3,761
Dec 2023 3,761
Jan 2024 3,761
Feb 2024 3,761
Mar 2024 3,761
Apr 2024 3,761
May 2024 3,761
Jun 2024 3,761
Jul 2024 3,853

Ono Pharmaceutical Co., Ltd. other data

  • What's the price of Ono Pharmaceutical Co., Ltd. stock today?

    One share of Ono Pharmaceutical Co., Ltd. stock can currently be purchased for approximately $11.4.

  • When is Ono Pharmaceutical Co., Ltd.'s next earnings date?

    Ono Pharmaceutical Co., Ltd. is estimated to report earnings on Tuesday, 28 Oct 2025.

  • Does Ono Pharmaceutical Co., Ltd. pay dividends?

    Yes, Ono Pharmaceutical Co., Ltd. pays dividends and its trailing 12-month yield is 2.77% with 31% payout ratio. The last Ono Pharmaceutical Co., Ltd. stock dividend of undefined was paid on 6 Sep 2025.

  • How much money does Ono Pharmaceutical Co., Ltd. make?

    Ono Pharmaceutical Co., Ltd. has a market capitalization of 10.48B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 12.41% to 502.67B US dollars. Ono Pharmaceutical Co., Ltd. earned 127.98B US dollars in net income (profit) last year or $0.24 on an earnings per share basis.

  • What is Ono Pharmaceutical Co., Ltd.'s stock symbol?

    Ono Pharmaceutical Co., Ltd. is traded on the OTC under the ticker symbol "OPHLF".

  • What is Ono Pharmaceutical Co., Ltd.'s primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers—General industry.

  • How do i buy shares of Ono Pharmaceutical Co., Ltd.?

    Shares of Ono Pharmaceutical Co., Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Ono Pharmaceutical Co., Ltd. have?

    As Jul 2024, Ono Pharmaceutical Co., Ltd. employs 3,853 workers, which is 2% more then previous month and 2% more then previous quarter.

  • When Ono Pharmaceutical Co., Ltd. went public?

    Ono Pharmaceutical Co., Ltd. is publicly traded company for more then 12 years since IPO on 21 Mar 2013.

  • What is Ono Pharmaceutical Co., Ltd.'s official website?

    The official website for Ono Pharmaceutical Co., Ltd. is ono-pharma.com.

  • How can i contact Ono Pharmaceutical Co., Ltd.?

    Ono Pharmaceutical Co., Ltd. can be reached via phone at +81 6 6263 5670.

Ono Pharmaceutical Co., Ltd. company profile:

Ono Pharmaceutical Co., Ltd.

ono-pharma.com
Exchange:

OTC

Full time employees:

3,687

Industry:

Drug Manufacturers—General

Sector:

Healthcare

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

8-2, Kyutaromachi 1-chome
Osaka, 541-8564

:
:
: